| Literature DB >> 27213347 |
Felicia Carotenuto1,2, Maria C Albertini3, Dario Coletti4, Alessandra Vilmercati5,6, Luigi Campanella7, Zbigniew Darzynkiewicz8, Laura Teodori9.
Abstract
The DNA damage response (DDR) is a molecular mechanism that cells have evolved to sense DNA damage (DD) to promote DNA repair, or to lead to apoptosis, or cellular senescence if the damage is too extensive. Recent evidence indicates that microRNAs (miRs) play a critical role in the regulation of DDR. Dietary bioactive compounds through miRs may affect activity of numerous genes. Among the most studied bioactive compounds modulating expression of miRs are epi-gallocatechin-3-gallate, curcumin, resveratrol and n3-polyunsaturated fatty acids. To compare the impact of these dietary compounds on DD/DDR network modulation, we performed a literature search and an in silico analysis by the DIANA-mirPathv3 software. The in silico analysis allowed us to identify pathways shared by different miRs involved in DD/DDR vis-à-vis the specific compounds. The results demonstrate that certain miRs (e.g., -146, -21) play a central role in the interplay among DD/DDR and the bioactive compounds. Furthermore, some specific pathways, such as "fatty acids biosynthesis/metabolism", "extracellular matrix-receptor interaction" and "signaling regulating the pluripotency of stem cells", appear to be targeted by most miRs affected by the studied compounds. Since DD/DDR and these pathways are strongly related to aging and carcinogenesis, the present in silico results of our study suggest that monitoring the induction of specific miRs may provide the means to assess the antiaging and chemopreventive properties of particular dietary compounds.Entities:
Keywords: bioactive compounds; chemoprevention; curcumin; epi-gallocatechin-3gallate; food; n3-PUFA; resveratrol
Mesh:
Substances:
Year: 2016 PMID: 27213347 PMCID: PMC4881573 DOI: 10.3390/ijms17050752
Source DB: PubMed Journal: Int J Mol Sci ISSN: 1422-0067 Impact factor: 5.923
MicroRNAs involved in DD/DDR processes.
| miRs | Reference |
|---|---|
| miR-34a/b/c, miR-192, miR-215, miR-16-1, miR-143, miR-107, let-7, miR-200c, miR-16, miR-145, miR-134, miR-449a/b, miR-503, miR-21, miR-24, miR-421, miR-504, miR-125b, miR-106b, miR-21, miR-210, miR-373, miR-100, miR-195, miR-124a, miR-290 cluster (miR-291-3p, miR-294, miR-295) | [ |
| miR-363, miR-25, miR-542 | [ |
| miR-421, miR-24, miR-34a/b/c, miR-504, miR-125b, miR-302, miR-92, miR-192, miR-194, miR-215, miR-106a-92 cluster (miR-106a, miR-18b, miR-20b, miR-19b-2, miR-92a-2, miR-363), miR-106b/25 cluster (miR-106b, miR-25, miR-93), miR-210, miR-128, miR-20, miR-130b, miR-143, miR-145, miR-16-1, miR-16, miR-103, miR-26a, miR-206 | [ |
| miR-15a, miR-29, miR-107, miR-605, miR-17-92 cluster (miR-17, miR-18a, miR-19a, miR-20a, miR-19b-1, miR-92a-1), miR-21-605, miR-221, miR-222, miR-138, miR-223, miR-181a, miR-27a, miR-214, miR-101, miR-185, miR-100, miR-506, miR-545, miR-124, miR-9, miR-182, miR-146a | [ |
MicroRNAs modulated by bioactive compounds; the effect on human normal or cancer cells.
| Compound | miRNA | Reference | Cells/Cancer | Dose/Duration |
|---|---|---|---|---|
| EGCG | miR-18, miR-16, let-7a, miR-221, miR-34b, miR-193b, miR-222, miR-342 | [ | hepatic cancer | 100 μM, 24 h |
| miR-636, miR-3907 | [ | normal dermal fibroblasts | 10 μM, 24 h | |
| miR-200c | [ | colorectal cancer cells and colon cancer stem cells | 100 μM, 24 h | |
| miR-210, miR-98-5p | [ | lung cancer | 40 μM, 9 h 10 μM, 24 h | |
| miR-1, miR-126 | [ | osteosarcoma | 0.08 g/L, 48 h 0.2 g/L, 72 h | |
| miR-194 | [ | hepatocarcinoma | 10 μg/mL, 48 h | |
| miR-7-1, miR-34a, miR-99a, miR-92, miR-93, miR-106b | [ | neuroblastoma | 50 μM, 24 h | |
| miR-25, miR-92, miR-141, miR-200a | [ | Hela cells and lymphoblasts | 1–5 μM, 24 h | |
| miR-33a, miR-122 | [ | hepatocarcinoma | 50 μM, 1 h | |
| EGCG | miR-92, miR-93, miR-106b, miR-7-1, miR-34a, miR-99a | [ | neuroblastoma | 50 μM, 24 h |
| miR-467bn, miR-487b, miR-197, miR-805, miR-374n, let-7f, miR-350, miR-24-1n, miR-137, miR-335-3p, let-7a, miR-222, miR-26b, miR-30c-1n, let-7d, miR-98, miR-30c, miR-30bn, miR-32, miR-674n, miR-532-5p, let-7g, miR-18a, miR-192, miR-302d, miR-30b, miR-802, let-7e, miR-322, miR-720, miR-146b, miR-340-3p, miR-185, miR-425, miR-10a, miR-126-5p, miR-101a, miR-30en, let-7c, miR-141, miR-33, miR-29an, miR-199b, miR-450a-5p, miR-21, miR-23a, miR-101b, miR-148a, miR-193, miR-23b, miR-107, miR-140, miR-551b, miR-466c-5p, miR-106a, miR-590-3p, miR-875-3p, miR-224, miR-292-5p, miR-678, miR-469, let-7bn, miR-463n, miR-574-3p, miR-201, miR-290-3p, miR-181a, miR-302a, miR-429, miR-133a, miR-190b, miR-710, miR-135b, miR-296-5p, miR-191n, miR-188-5p, miR-298, miR-181a-1n, miR-466g, miR-26bn, miR-466f-3p, miR-29bn, miR-1224, miR-291b-5p, miR-324-5p, miR-486, miR-128, miR-450b-3p, miR-135an, miR-294, miR-671-5p, miR-878-3p, miR-801, miR-370, miR-1, miR-494, miR-133b | [ | hepatocarcinoma | 100 μM, 24 h | |
| CRC | miR-192-5p/215 | [ | lung cancer | 15 μM, 48 h |
| miR-7 | [ | pancreatic cancer | 3–6 μM, 72 h | |
| miR-22 | [ | retinoblastoma | 20 μM, 48 h | |
| miR-27a | [ | colon cancer | 2.5–10 μg/mL, 24 h | |
| miR-21 | [ | |||
| let-7a, miR-21, miR-34a | [ | esophageal cancer | 30 μM, 24 h | |
| miR-221 | [ | pancreatic cancer | 500 nM of synthetic CRC analogue, 72 h | |
| CRC | miR-27a, miR-20a, miR-17-5p, miR-21 | [ | colon carcinoma | 30 μM, 24 h |
| miR-203 | [ | bladder carcinoma | 10 μM, 3 days | |
| miR-320, miR-26a, let-7i, miR-130a, miR-16, miR-125b, miR-23a, miR-27b, miR-155, miR-625, miR-576-3p, miR-186n, miR-9n, let-7i | [ | lung adenocarcinoma | 15 μM, 48 h | |
| miR-15a, miR-16-1 | [ | leukemic cells | 5–20 μM, 24-72 h | |
| miR15a, miR-16 | [ | breast cancer | 10–60 μM, 24 h | |
| miR-103, miR-140, miR-146b, miR-148a, miR-15b, miR-181a, miR-181b, miR-181d, miR-195, miR-196a, miR-199an, miR-19a, miR-204, miR-20a, miR-21, miR-22, miR-23a, miR-23b, miR-24, miR-25, miR-26a, miR-27a, miR-34a, miR-374, miR-510, miR-7, miR-92, miR-93, miR-98 | [ | pancreatic cancer | 10 μM, 72 h | |
| RSV | miR-663, miR-744m | [ | breast cancer | 100 μM, 24 h |
| miR-21 | [ | pancreatic cancer | 50 μM, 24 h | |
| miR-520h | [ | lung cancer | 10–20 μM, 48 h | |
| miR-21, miR-181b, miR-663, miR-30c2 | [ | peripheral blood mononuclear cells from hypertensive patients | RSV (8 mg) grape extract, one year daily intake (
| |
| miR-150, miR-296-5p | [ | lymph node cancer prostate | 50 μM, 24 h | |
| miR-33a, miR-122 | [ | hepatocarcinoma | 50 μM, 1 h | |
| miR-155 miR-663 | [ | monocytic cells | 30–50 μM, 14 h | |
| RSV | miR-155, miR-34a | [ | EBV-immortalized B cells | 25–50 μM, 24 h |
| miR-7, miR-17, miR-18b, miR-20a, miR-20b, miR-92b, miR-106a, miR106b, miR-17-5p, miR-20a, miR-106b, miR-17-92 cluster, miR-106ab clusters | [ | prostate cancer | 50–100 μM, 24 h | |
| miR-622 | [ | bronchial epithelial cells | 50 μM, 48 h | |
| miR-155, miR-633 | [ | monocytes | 30 μM, 14 h | |
| let-7c, miR-106a, miR-106b, miR-1224-5p, miR-1228, miR-231, miR-1246, miR-1260, miR-1267, miR-1268, miR-129, miR-1290, miR-1308, miR-1469, miR-149, miR-150, miR-152, miR-15a, miR-17, miR-1825, miR-185, miR-18b, miR-1908, miR-1915, miR-197, miR-1972, miR-1973, miR-1974, miR-1975, miR-1977, miR-1979, miR-20a, miR-20b, miR-24, miR-296-5p, miR-483-5p, miR-513a-5p, miR-548q, miR-572, miR-575, miR-612, miR-638, miR-654-5p, miR-659, miR-671-5p, miR-7, miR-762, miR-764, miR-874, miR-92b, miR-939 | [ | lymph node cancer prostate | 50 μM, 48 h | |
| miR-1, miR-100-1/2, miR-102, miR-103-1, miR-103-2, miR-146a, miR-146b-5p, miR-16-0, miR-17, miR-181a2, miR-194-2, miR-196a1, miR-205, miR-206, miR-21, miR-23a, miR-23b, miR-25, miR-26a, miR-29c, miR-30a-3p, miR-30c-1, miR-30d, miR-30e-5p, miR-323, miR-340, miR-363n-5p, miR-424, miR-494, miR-497, miR-560, miR-560, miR-565, miR-565, miR-572, miR-574, miR-594, miR-615, miR-622, miR-629, miR-631, miR-638, miR-639, miR-657, miR-659, miR-663, miR-801, miR-92a-2 | [ | colorectal carcinoma | 50 μM, 14 h | |
| n3-PUFA | miR-192, miR-30c, miR-141-3p, miR-221-3p, miR-1283, let-7f, miR-181a-5p, miR-1, miR-30a | [ | Caco-2 cells | 200 μM DHA in lipid micelles, 24 h |
| n3-PUFA | miR-26a, miR-26b | [ | cholangiocarcinoma | 50 μM DHA, 12 h |
| miR-221 | [ | endothelial progenitor cells | 25–125 μM EPA, 4 h | |
| miR-146, miR-181a | [ | glioma | 25–50 μM DHA, 48 h | |
| miR-21 | [ | breast cancer | 152 nM DHA, 24 h | |
| miR-30c, miR-20b, miR-16, miR-22, miR-145, miR-34, miR-25, miR-17, miR-26a, miR-29c, miR-200a, miR-206, miR-323, miR-16, miR-22, miR-20b, miR-30c, miR-183, miR-224, miR-145, miR-181a, miR-208, miR-143, miR-20a, miR-149, miR-125b | [ | glioma | 50–100 μM DHA, 24 h |
Figure 1Venn diagram showing the microRNAs involved in DD/DDR (ellipse, grey) and identified as modulated by bioactive compounds: EGCG (epi-gallocatechin-3-gallate; green), CRC (curcumin; blue), RSV (resveratrol; pink) and n3-PUFAs (n3-polyunsaturated fatty acids, yellow). The common miRNAs, modulated by all four compounds, are indicated in red (miR-16, miR-25, miR-21, miR-181a, miR-146b, miR-34a).
Enriched KEGG pathways for predicted targets of the DD/DDR microRNAs modulated by all four compounds.
| KEGG Pathway | #of Genes | miRNAs | |
|---|---|---|---|
| Fatty acid biosynthesis | 0 | 4 | miR-16 |
| Fatty acid metabolism | 2.23 × 10-5 | 7 | miR-16 |
| Thyroid hormone synthesis | 2.58 × 10-5 | 5 | miR-146b |
| Signaling pathways regulating pluripotency of stem cells | 0.0002346931 | 24 | miR-16 |
| Glioma | 0.000556152 | 15 | miR-16 miR-34a |
| Glycosphingolipid biosynthesis: lacto and neolacto series | 0.001440903 | 2 | miR-34a |
| Hippo signaling pathway | 0.00410767 | 24 | miR-16 miR-21 |
| Steroid hormone biosynthesis | 0.009497578 | 1 | miR-25 |
| Ovarian steroidogenesis | 0.01398717 | 1 | miR-25 |
| Melanoma | 0.01891852 | 14 | miR-16 |
| Prostate cancer | 0.02681897 | 16 | miR-16 |
| Cytokine-cytokine receptor interaction | 0.03260184 | 11 | miR-21 |
| mTOR signaling pathway | 0.03417768 | 13 | miR-16 miR-25 |
| Oocyte meiosis | 0.03995201 | 16 | miR-16 |
DIANA-miRPath v3.0 [66] was used to predict the targeted KEGG pathways by miRs involved in DD/DDR signaling and modulated by all considered compounds (EGCG, CRC, RSV and n3-PUFAs). The target prediction threshold was set at 0.85. p-value < 0.05. #: number.
Enriched KEGG pathways for predicted targets of the DD/DDR microRNAs modulated by EGCG.
| KEGG Pathway | # of Genes | # of miRNAs | |
|---|---|---|---|
| Fatty acid biosynthesis | 0 | 4 | 3 |
| ECM-receptor interaction | 0 | 42 | 13 |
| Signaling pathways regulating pluripotency of stem cells | 2.44 × 10−9 | 76 | 17 |
| Amebiasis | 3.53 × 10−6 | 24 | 6 |
| Proteoglycans in cancer | 1.17 × 10−4 | 117 | 12 |
| Mucin type | 1.67 × 10−2 | 15 | 10 |
| Glioma | 1.43 × 10−1 | 39 | 10 |
| TGF-β signaling pathway | 1.85 × 100 | 40 | 8 |
| Fatty acid metabolism | 2.28 × 101 | 9 | 3 |
| Focal adhesion | 0.0002057474 | 110 | 7 |
| PI3K-Akt signaling pathway | 0.001829865 | 138 | 7 |
| Lysine degradation | 0.006232265 | 18 | 7 |
| ErbB signaling pathway | 0.02315742 | 45 | 7 |
| Protein digestion and absorption | 0.02773474 | 26 | 3 |
| Thyroid hormone signaling pathway | 0.03049808 | 57 | 8 |
| Glycosaminoglycan biosynthesis heparan sulfate/heparin | 0.05012798 | 9 | 5 |
DIANA-miRPath v3.0 was used to predict the targeted KEGG pathways by miRs involved in DDR signaling and that were EGCG modulated. The target prediction threshold was set at 0.85. p-value < 0.05. #: number.
Enriched KEGG pathways for predicted targets of the DDR microRNAs modulated by CRC.
| KEGG Pathway | # of Genes | # of miRNAs | |
|---|---|---|---|
| Fatty acid biosynthesis | 0 | 4 | 5 |
| ECM-receptor interaction | 0 | 19 | 7 |
| Fatty acid metabolism | 6.88 × 10−9 | 8 | 4 |
| Signaling pathways regulating pluripotency of stem cells | 2.16 × 10−5 | 55 | 9 |
| Glioma | 0.0002249224 | 20 | 5 |
| Proteoglycans in cancer | 0.0003169881 | 66 | 6 |
| TGF-β signaling pathway | 0.006985672 | 28 | 5 |
| Prostate cancer | 0.009151789 | 31 | 5 |
| Axon guidance | 0.01011865 | 45 | 3 |
| Melanoma | 0.01304415 | 20 | 4 |
| Prolactin signaling pathway | 0.01811186 | 28 | 5 |
| Pathways in cancer | 0.0206275 | 70 | 4 |
| Glycosaminoglycan biosynthesis-heparan sulfate/heparin | 0.02616968 | 3 | 5 |
DIANA-miRPath v3.0 was used to predict the targeted KEGG pathways by miRs involved in DDR signaling and that were CRC modulated. The target prediction threshold was set at 0.85. p-value < 0.05. #: number.
Enriched KEGG pathways for predicted targets of the DDR microRNAs modulated by RSV.
| KEGG Pathway | # of Genes | # of miRNAs | |
|---|---|---|---|
| Fatty acid biosynthesis | 0 | 5 | 7 |
| Fatty acid metabolism | 0 | 16 | 8 |
| Signaling pathways regulating pluripotency of stem cells | 1.07 × 10−6 | 64 | 13 |
| TGF-β signaling pathway | 1.39 × 10−4 | 34 | 9 |
| Proteoglycans in cancer | 8.1 × 10−1 | 70 | 10 |
| Axon guidance | 0.0009836851 | 55 | 6 |
| Hippo signaling pathway | 0.001005551 | 43 | 9 |
| Mucin type | 0.002219981 | 12 | 8 |
| Glycosphingolipid biosynthesis: lacto and neolacto series | 0.006851962 | 6 | 7 |
| GABAergic synapse | 0.007317003 | 13 | 8 |
| Glioma | 0.03097475 | 21 | 7 |
DIANA-miRPath v3.0 was used to predict the targeted KEGG pathways by miRs involved in DDR signaling and that were RSV modulated. The target prediction threshold was set at 0.85. p-value < 0.05. #: number.
Enriched KEGG pathways for predicted DDR targets of the microRNAs modulated by n-3-PUFAs.
| KEGG Pathway | # of Genes | # of miRNAs | |
|---|---|---|---|
| ECM-receptor interaction | 0 | 27 | 4 |
| Fatty acid biosynthesis | 5.57 × 10-5 | 4 | 1 |
| Glycosphingolipid biosynthesis: lacto and neolacto series | 2.21 × 10-2 | 8 | 8 |
| Mucin type | 0.0003249162 | 9 | 5 |
| Proteoglycans in cancer | 0.0004576113 | 76 | 8 |
| TGF-β signaling pathway | 0.001807704 | 27 | 5 |
| Thyroid hormone synthesis | 0.002952912 | 5 | 3 |
| Amebiasis | 0.00834241 | 24 | 2 |
| Signaling pathways regulating pluripotency of stem cells | 0.02548584 | 51 | 4 |
| Glioma | 0.02578235 | 31 | 6 |
DIANA-miRPath v3.0 was used to predict the targeted KEGG pathways by miRs involved in DDR signaling and that were n3-PUFAs modulated. The target prediction threshold was set at 0.85. p-value < 0.05. #: number.
Figure 2Binary heat map of pathways related to the common microRNAs involved in DDR signaling and modulated by all of the compounds: EGCG, CRC, RSV, n3-PUFAs. In this plot, heat map calculation is based on binary p-values (0: not targeted, 1: targeted); all significantly targeted pathways are marked with deep red. The plot shows miRNAs targeting similar pathways and pathways being targeted by miRNAs.
Figure 3MicroRNAs involved in DDR and modulated by EGCG versus the pathways’ heat map. In this plot, heat map calculation is based on absolute p-values. Darker colors represent lower p-values (higher significance). The plot shows miRNAs targeting similar pathway clusters and pathways being targeted by miRNA groups.
Figure 4MicroRNAs involved in DDR and modulated by CRC versus the pathways’ heat map. In this plot, heat map calculation is based on absolute p-values. Darker colors represent lower p-values (higher significance). The plot shows microRNAs targeting similar pathway clusters and pathways being targeted by miRNA groups.
Figure 5MicroRNAs involved in DDR and modulated by RSV versus the pathways’ heat map. In this plot, heat map calculation is based on absolute p-values. Darker colors represent lower p-values (higher significance). The plot shows microRNAs targeting similar pathway clusters and pathways being targeted by miRNA groups.
Figure 6MicroRNAs involved in DDR and modulated by n3-PUFAs versus the pathways’ heat map. In this plot, heat map calculation is based on absolute p-values. Darker colors represent lower p-values (higher significance). The plot shows miRNAs targeting similar pathway clusters and pathways being targeted by miRNA groups.